Patent Publication Number: US-11383047-B2

Title: Drug delivery system with temperature-sensitive control

Description:
CROSS-REFERENCE TO RELATED APPLICATIONS 
     This is a continuation of U.S. patent application Ser. No. 14/913,928, filed Feb. 23, 2016, which is the US National Phase of International Patent Application No. PCT/US14/61680, having an international filing date of Oct. 22, 2014, and which claims the priority benefit of U.S. Provisional Application No. 61/895,285, filed Oct. 24, 2013. The entire contents of each of the foregoing is expressly incorporated herein by reference. 
    
    
     BACKGROUND 
     This patent is directed to a drug delivery system and, in particular, to a drug delivery system including temperature-sensitive control of drug delivery and/or the drug delivery system. 
     Patients commonly receive drugs to treat a wide variety of medical conditions. While certain drugs may be administered via peroral, topical, transmucosal, or inhalation routes, other drugs are administered via injection or infusion. These injections or infusions may include intradermal, subcutaneous, intramuscular, intravenous, and intraperitoneal methods. Typically, injections or infusions involve the use of a hollow cannula or needle through which the drug passes from a container to the patient. 
     With regard to the subcutaneous and intramuscular injection routes, considerable attention has been devoted to providing a reproducible motion relative to the insertion of the cannula or needle through the skin to position the needle at a proper distance into the body, and then to provide a reproducible rate of delivery through the cannula or needle into the patient. Very often, providing a reproducible rate of delivery involves providing a reproducible motion for the movement of a plunger along the inside of a syringe or cartridge. Various mechanisms have been designed for controlled release of stored energy to advance the needle into the patient, and then to advance the plunger relative to the bore of the syringe or cartridge. Springs, motors, chemical reactions, and phase-changing materials have all been considered to provide the motive force for advancement of the needle and/or the plunger. Reproducible motion is considered fundamental to predictable drug delivery. 
     To the extent that a controller is included in such a drug delivery device, the controller controls the source of stored energy to ensure that it is released in a reproducible fashion. This may involve ensuring that various springs or motors are actuated such that one motion follows another in a predetermined sequence, thereby ensuring safe and effective delivery of the drug via the cannula or needle into the patient. 
     SUMMARY 
     According to an aspect of the present disclosure, a drug delivery system includes a reservoir adapted to contain a drug, and a drug delivery device coupled to the reservoir to deliver a drug from the reservoir. The drug delivery device also includes a lock having a locked state wherein delivery of the drug from the reservoir is limited and an unlocked state wherein delivery of the drug from the reservoir is not limited. The system further includes a temperature sensor, an output device, and a controller coupled to the lock, the temperature sensor, and the output device. The controller is programmed (a) to determine if the temperature of a drug disposed in the reservoir exceeds an upper limit, and if the temperature exceeds the upper limit, to activate the output device at least once and to place the lock in the locked state, (b) to determine if the temperature of a drug disposed in the reservoir is below a lower limit, and if the temperature is below the lower limit, to activate the output device at least once and to place the lock in the locked state, and (c) to determine if the temperature of the drug is between the upper limit and the lower limit subsequent to (b), and if the temperature is between the upper limit and the lower limit, to place the lock in the unlocked state. 
     According to another aspect of the present disclosure, a drug delivery system includes a reservoir adapted to contain a drug, and a drug delivery device coupled to the reservoir to deliver a drug from the reservoir. The drug delivery device also includes at least one temperature-sensitive component and a lock having a locked state wherein delivery of the drug from the reservoir is limited and an unlocked state wherein delivery of the drug from the reservoir is not limited. The system further includes a temperature sensor, an output device, and a controller coupled to the lock, the temperature sensor, and the output device. The controller is programmed (a) to determine if the temperature of the at least one temperature-sensitive component exceeds an upper limit, and if the temperature exceeds the upper limit, to activate the output device at least once and to place the lock in the locked state, (b) to determine if the temperature of the at least one temperature-sensitive component is below a lower limit, and if the temperature is below the lower limit, to activate the output device at least once and to place the lock in the locked state, and (c) to determine if the temperature of the at least one temperature-sensitive component is between the upper limit and the lower limit subsequent to (b), and if the temperature is between the upper limit and the lower limit, to place the lock in the unlocked state. 
     According to a further aspect of the present disclosure, a drug delivery system includes a reservoir adapted to contain a drug, and a drug delivery device coupled to the reservoir to deliver a drug from the reservoir. The drug delivery device also includes a lock having a locked state wherein delivery of the drug from the reservoir is limited and an unlocked state wherein delivery of the drug from the reservoir is not limited. The system further includes a temperature sensor, an output device, and a controller coupled to the lock, the temperature sensor, and the output device. The controller is programmed (a) to determine if the temperature of a drug disposed in the reservoir exceeds an upper limit, and if the temperature exceeds the upper limit, to activate the output device at least once and to place the lock in the locked state, (b) to determine if temperature of a drug disposed in the reservoir is below a lower limit, and if the temperature is below the lower limit, to activate the output device at least once and to place the lock in the locked state, and (c) to determine if a time period has elapsed subsequent to (b), and if the time period has elapsed, to place the lock in the unlocked state. 
     According to a still further aspect of the present disclosure, a drug delivery system includes a reservoir adapted to contain a drug, and a drug delivery device coupled to the reservoir to deliver a drug from the reservoir. The drug delivery device also includes a lock having a locked state wherein delivery of the drug from the reservoir is limited and an unlocked state wherein delivery of the drug from the reservoir is not limited. The system further includes an output device, and a controller coupled to the lock and the output device. The controller includes a temperature sensor, and is configured to (a) to determine if the temperature of a drug disposed in the reservoir is below a lower limit, and if the temperature is below the lower limit, to activate the output device at least once and to place the lock in the locked state, and (b) to determine if the temperature of the drug is between the upper limit and the lower limit subsequent to (a), and if the temperature is between the upper limit and the lower limit, to place the lock in the unlocked state. In addition or in the alternative, this controller may be configured to determine if the drug is above an upper limit, and if so, take appropriate action. 
     According to yet another aspect of the present disclosure, a method of delivering a drug product includes determining if the temperature of a drug disposed in a reservoir of a drug delivery system is below a lower limit, and if the temperature is below the lower limit, to activate an output device at least once; and providing instructions to a user of the drug delivery system that if the output device is activated, to operate the drug delivery system only after a period of time has elapsed after the output device has been activated. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
       The disclosure will be more fully understood from the following description taken in conjunction with the accompanying drawings. Some of the figures may have been simplified by the omission of selected elements for the purpose of more clearly showing other elements. Such omissions of elements in some figures are not necessarily indicative of the presence or absence of particular elements in any of the exemplary embodiments, except as may be explicitly delineated in the corresponding written description. None of the drawings are necessarily to scale. 
         FIG. 1  is a schematic view of a drug delivery system according to one embodiment of the disclosure; 
         FIG. 2  is a block diagram of the operation of a drug delivery system such as illustrated in  FIG. 1  according to an embodiment addressing high and low temperature conditions of the drug and controlling delivery directly according to temperature; 
         FIG. 3  is a block diagram of the operation of a drug delivery system such as illustrated in  FIG. 1  according to an embodiment addressing high and low temperature conditions of the drug and controlling delivery directly according to a lapse of time, and indirectly according to temperature; 
         FIG. 4  is a block diagram of the operation of a drug delivery system such as illustrated in  FIG. 1  according to an embodiment addressing high and low temperature conditions of the drug delivery device and controlling delivery according to temperature; 
         FIG. 5  is a block diagram of the operation of a drug delivery system such as illustrated in  FIG. 1  according an embodiment addressing high temperature conditions of the drug with removal/replacement; 
         FIG. 6  is a block diagram of the operation of a drug delivery system such as illustrated in  FIG. 1  according to an embodiment addressing low temperature conditions of the drug through incorporation of a heater; 
         FIG. 7  is a block diagram of the operation of a drug delivery system such as illustrated in  FIG. 1  according an embodiment addressing high temperature conditions of the drug with removal/replacement and addressing low temperature conditions as to the drug through incorporation of a heater; 
         FIG. 8  is a perspective view of a drug delivery system according to an embodiment of the present disclosure, with an associated syringe which may be used to fill the device; 
         FIG. 9  is a cross-sectional view of the drug delivery device of  FIG. 8  taken along line  9 - 9 ; 
         FIG. 10  is a cross-sectional view of the drug delivery device of  FIG. 9  taken along line  10 - 10 ; 
         FIG. 11  is a schematic view of a drive for use in the drug delivery system according to  FIG. 8 ; 
         FIG. 12  is an enlarged, fragmentary, cross-sectional view of a barrier system used in conjunction with a needle according to the disclosure, with the needle in a retracted state; 
         FIG. 13  is an enlarged, fragmentary, cross-sectional view of the barrier system of  FIG. 12 , with the needle in a deployed state; 
         FIG. 14  is a cross-sectional view illustrating the placement of the temperature sensor; 
         FIG. 15  is a schematic view of a mechanical controller according to the disclosure; 
         FIG. 16  is a block diagram of the operation of a drug delivery system such as illustrated in  FIG. 1  according to an embodiment addressing high and low temperature conditions of the drug and controlling delivery directly according to temperature; and 
         FIG. 17  is a block diagram of the operation of a drug delivery system such as illustrated in  FIG. 1  according to an embodiment addressing high and low temperature conditions of the drug and passively controlling delivery according to temperature. 
     
    
    
     DETAILED DESCRIPTION OF VARIOUS EMBODIMENTS 
     A drug may be injected or infused using a variety of different approaches, technologies, and systems. For example, the drug may be filled into a reservoir in the form of a syringe, and then the syringe may be used to administer (inject) the drug subcutaneously. Alternatively, the drug may be filled into a reservoir in the form of a syringe or other appropriate primary container, e.g., a cartridge, and then the pre-filled syringe or other container may be combined with an autoinjector that may be used to automate the movement of a plunger within the bore of the syringe or container, and optionally the insertion of a cannula or needle into the patient. For example, the autoinjector may include a drive (e.g., a motor, spring(s), propellant reservoir, etc.) that causes the container to move within a housing and/or the plunger to move within the container upon manipulation of an actuator (e.g., depressing a button). As a still further alternative, the drug may be filled into a reservoir (or container), and the reservoir may be manipulated with a pump or drive (which may take the form of a motor, spring(s), propellant reservoir, etc.) that infuses the drug through a needle, cannula or catheter into the patient. The pump and the reservoir may be disposed within a housing, which housing may be attached to the patient to form an on-body drug delivery system, for example. 
     In whatever form the drug delivery system may take, it remains important to follow the appropriate storage recommendations for the drug to be injected or infused, because failure to follow these recommendations can result in subpotent or incomplete delivery of pharmaceutical products, and potentially therapeutic failure. For example, the storage recommendations for certain products require storage at low temperatures (2-8° C.), i.e., refrigeration. If the pharmaceutical product is exposed to temperatures outside the recommended range, the product may become compromised and it may be necessary to discard the product. Exposure to temperatures outside the recommended range may occur naturally with exposure to environmental conditions. 
     Given the variety of different approaches, technologies, and systems for drug delivery, there are a number of different options for storage of the drug and the associated drug delivery device. For example, the drug may be refrigerated in its (primary) container or reservoir (e.g., pre-filled syringe, cartridge, etc.), while the associated drug delivery device (e.g., autoinjector, on-body drug delivery system) may be stored at room temperature, the reservoir being combined with the remainder of the drug delivery device at the time of use. Alternatively, the drug (positioned in its container or reservoir) and the associated drug delivery device may be refrigerated together. For example, the reservoir may be combined with the associated drug delivery device prior to or during refrigeration, such that the device is already assembled for use upon removal from storage. It is also possible that the drug-filled container and the drug delivery device may be disposed in the same packaging for storage (e.g., as a kit), but the drug-filled reservoir has not been disposed within the drug delivery device. 
     Storage of certain drug products (with or without the associated drug delivery device) at low temperatures may be important to prevent a subpotent product or incomplete or suboptimal delivery. For example, storage at low temperature may affect the physical characteristics of drug product or the action of the drug delivery device. Certain drug products exhibit increased viscosity at lower temperatures, which may inhibit delivery or make the rate of delivery less predictable soon after removal from the low temperature. Other drug products may become more viscous with increased temperature and therefore more difficult or less predictable to deliver the longer the drug is kept at room temperature. In addition, if the drug device is refrigerated with the drug, the storage at low temperatures may affect the performance of the drug delivery device. For example, the electrical discharge of batteries is known to change with temperature, providing less energy at reduced temperature, which may make delivery more difficult or less predictable soon after the device is removed from refrigeration where the drive relies upon an on-board battery. Further, storage at low temperatures may affect patient comfort when the drug is delivered. Certain patients will find administration of low temperature fluids to be painful. In addition, reductions in the rate of injection/infusion caused by low temperature effects on the drug and/or the device may be considered to be painful. 
     Once the drug product (and optionally the drug delivery device) is removed from storage, exposure to high temperatures may result in suboptimal drug delivery or delivery of a subpotent drug product. As noted above, depending on the storage recommendations, exposure to too high temperatures may require disposal of the drug product. Exposure to too high temperatures may also affect components of the drug delivery device, such as the battery. 
     This disclosure focuses on a drug delivery system that is sensitive to the temperature changes that the drug and/or device may undergo, and considers these temperature changes in controlling the delivery of the drug and/or operation of the drug delivery device. As a consequence, the drug delivery system according to the present disclosure may alter its operation based on the temperature of the drug and/or the device to ensure that the delivery of the drug is safe, comfortable, and predictable over a wide range of environmental and operating conditions. 
       FIG. 1  is a schematic of a drug delivery system  100  according to one embodiment of the disclosure. The drug delivery system  100  includes a number of components or subassemblies, such as a reservoir  102 , a drug delivery device  104 , a temperature sensor  106 , an output device  108 , and a controller  110 . The details of each of these components or subassemblies will be discussed below relative to a series of non-limiting examples. 
     The reservoir  102  is adapted to contain a drug. The drug delivery device  104  is coupled to the reservoir  102  to deliver the drug from the reservoir  102 . The drug delivery system  100  includes a lock  112  having a locked state wherein delivery of the drug from the reservoir  102  is limited and an unlocked state wherein delivery of the drug from the reservoir  102  is not limited. According to certain embodiments, the lock  112  may substantially prevent delivery of the drug from the reservoir  102  by disposing or maintaining a physical barrier between the drug delivery device  104  and the reservoir  102 , or by preventing the operation of the drug delivery device  104 . According to some embodiments, the substantial prevention of the delivery of the drug from the reservoir  102  may mean that flow of the drug from the reservoir  102  through the drug delivery device  104  is less than about 15%, 10%, 5% or 1% of the flow of the drug from the reservoir  102  through the drug delivery device  104  in the unlocked state. In addition, in some embodiments, the lock  112  in the unlocked state may move or remove the physical barrier between the drug delivery device  104  and the reservoir  102 , or may permit the drug delivery device  104  to operate. According to certain embodiments, permitting the delivery of the drug from the reservoir  102  may mean that flow of the drug from the reservoir  102  through the drug delivery device  104  is at least about 85%, 90%, 95% or 99% of the maximum flow possible of the drug from the reservoir  102  through the drug delivery device  104 . 
     In some embodiments, the controller  110  is coupled to the lock  112 , the temperature sensor  106 , and the output device  108 . The controller  110  may include a processor and memory, which processor may be programmed to receive a signal or signals from the temperature sensor  106  and control (e.g., activate) the output device  108  and the lock  112 . Alternatively, the controller  110  may be a mechanical device or assembly that integrates functions of the temperature sensor  106  and the lock  112  while controlling or actuating the output device  108 . For example, the controller  110  may include a strip of shape memory metal that assumes a particular shape when the metal is above or below a particular temperature threshold, the strip being secured relative to a fluid flow path (e.g., tubing) that connects the reservoir  102  to the drug delivery device  104  such that when the strip assumes the afore-mentioned shape, the strip impinges on the fluid flow path so as to open or close the fluid flow path. The strip may thus function as the temperature sensor  106  and the lock  112 , as well as being part of the controller  110 . It will also be recognized that the controller may include mechanical and electrical components or subassemblies, as well as chemical or biologic components or subassemblies. 
     According to some embodiments and as illustrated in  FIGS. 1 and 2 , the controller  110  may be configured to determine (e.g., in the case of an electrical embodiment, be programmed to determine) if the temperature of the drug disposed in the reservoir  102  exceeds an upper limit at block  130 . According to some embodiments, the determination may be based on a signal received by the controller  110  from the temperature sensor  106 . If the temperature exceeds the upper limit at block  130 , the controller  110  may activate the output device  108  at least once at block  132  (e.g., to alert the user that the temperature of the drug is too high for safety) and place the lock  112  in the locked state at block  134 . If the temperature is below the upper limit at block  130 , the controller  110  may determine (or may be programmed to determine) if the temperature of the drug disposed in the reservoir  102  is below a lower limit at block  136 , and if the temperature is below the lower limit, may activate the output device  108  at least once at block  138  (e.g., to alert the user that the temperature of the drug is too low for safety, for comfortable delivery and/or for predictable delivery) and place the lock  112  in the locked state at block  140 . Further, the controller  110  may determine (or may be programmed to determine) at block  142  if the temperature of the drug is between the upper limit and the lower limit subsequent to block  136  (and blocks  138 ,  140 ), and if the temperature is between the upper limit and the lower limit, to place the lock  112  in the unlocked state at block  144  thus permitting operation at block  146 . This last step may be combined with activation of the output device  108  to alert the user that the device is within acceptable range for delivery. 
     According to other embodiments and as illustrated in  FIGS. 1 and 3 , the controller  110  may determine if the temperature of the drug disposed in the reservoir  102  exceeds an upper limit (for example, by receiving a signal from the temperature sensor  106 ) at block  150 , and if the temperature exceeds the upper limit, may activate the output device  108  at least once at block  152  and place the lock  112  in the locked state at block  154 . The controller  110  may also be programmed to determine if the temperature of a drug disposed in the reservoir  102  is below a lower limit (by receiving a signal from the temperature sensor  106 ) at block  156 , and if the temperature is below the lower limit, may activate the output device  108  at least once at block  158  and place the lock  112  in the locked state at block  160 . Further, the controller  110  may determine at block  162  if a time period has elapsed subsequent to block  156  (and blocks  158 ,  160 ), and if the time period has elapsed, may place the lock  112  in the unlocked state at block  164  thus permitting operation at block  166 . In some embodiments, where the controller  110  includes a processor, the controller  110  may be programmed to carry out the afore-mentioned determinations and activations of  FIG. 3 , or the controller  110  may be configured to perform those actions. 
     According to other embodiments and as illustrated in  FIGS. 1 and 4 , the drug delivery device  104  may optionally include at least one temperature-sensitive component (“T-Sens. Comp.”)  114  and the lock  112  having a locked state wherein delivery of the drug from the reservoir  102  is limited and an unlocked state wherein delivery of the drug from the reservoir  102  is not limited. According to such an embodiment, the controller  110  would be coupled to the lock  112 , an optional (or additional) temperature sensor  106 , and the output device  108 , and would determine if the temperature of the at least one temperature-sensitive component  114  exceeds an upper limit at block  170 , and if the temperature exceeds the upper limit, may activate the output device  108  at least once at block  172  and place the lock  112  in the locked state at block  174 . The controller  110  may also determine if the temperature of the at least one temperature-sensitive component  114  is below a lower limit at block  176 , and if the temperature is below the lower limit, may activate the output device  108  at least once at block  178  and place the lock  112  in the locked state at block  180 . The controller  110  may be configured to determine at block  182  if the temperature of the at least one temperature-sensitive component  114  is between the upper limit and the lower limit subsequent to block  176 , and if the temperature is between the upper limit and the lower limit, place the lock  112  in the unlocked state at block  184  permitting operation at block  186 . Again, where the controller  110  includes a processor, the controller  110  may be programmed to carry out the afore-mentioned determinations and activations, or the controller  110  may be otherwise configured to perform those actions. According to such an embodiment, at least one temperature-sensitive component  114  may be a battery. 
     Further refinements may be included in any of the foregoing embodiments. 
     For example, the reservoir  102  may adapted to be removed from the drug delivery system  100 . According to such embodiments and as illustrated in  FIGS. 1 and 5 , the controller  110  is configured or programmed to determine if the temperature of the drug in the reservoir  102  exceeds a particular temperature at block  190 . After determining that the temperature exceeds a threshold temperature at block  190  (and after activating the output device at block  192  and the lock at block  194 ), the controller  110  may determine (or may be programmed to determine) at block  196  if the reservoir  102  has been removed and replaced with another reservoir  102  adapted to contain a drug subsequent to block  190 . If the reservoir  102  has been removed and replaced with another reservoir  102 , the controller  110  may place the lock  112  in the unlocked state at block  198 . The device may then again determine if the temperature of the drug disposed in the reservoir  102  is above the upper limit at block  190  and, if it is not, the device may then determine is the temperature of the drug disposed in the reservoir  102  is below a lower limit at block  200 . If the temperature of the drug in the reservoir  102  is below the lower limit, the device may activate the output device  108  at least once at block  202  and place the lock  112  in the locked state at block  204 . Further, the controller  110  may determine (or may be programmed to determine) at block  206  if the temperature of the drug is between the upper limit and the lower limit subsequent to block  200  (and blocks  202 ,  204 ), and if the temperature is between the upper limit and the lower limit, to place the lock  112  in the unlocked state at block  208  thus permitting operation at block  210 . It will be recognized that such a method may also be adapted to permit the determination of a high temperature condition of a temperature-sensitive component  114  of the drug delivery system (e.g., a battery), and the monitoring of the replacement of the battery and subsequent operation of the system  200 . 
     According to other embodiments, the drug delivery system  100  may include a heater  116  coupled to the controller  110  and proximate to at least one of the reservoir  102  and the drug delivery device  104  (see  FIG. 1 ). As illustrated in  FIGS. 1 and 6 , the controller  110  may determine (or in the case of an electrical embodiment, may be programmed to determine) if the temperature of a drug disposed in the reservoir  102 , for example, exceeds an upper limit at block  230 . If the temperature exceeds the upper limit, the controller  110  may activate the output device  108  at least once at block  232  and place the lock  112  in the locked state at block  234 . If the temperature is below the upper limit, the controller  110  may determine (or may be programmed to determine) if the temperature of a drug disposed in the reservoir  102  is below a lower limit at block  236 , and if the temperature is below the lower limit, may activate the output device  108  at least once at block  238  and place the lock  112  in the locked state at block  240 . Further, the controller  110  may determine (or may be programmed to determine) at block  242  if the temperature of the drug is between the upper limit and the lower limit subsequent to block  236  (and blocks  238 ,  240 ), and the controller  110  may be programmed to activate the heater  116  at block  244  if the temperature of the drug is below the lower limit, and to deactivate the heater  116  at block  246  if the temperature of the drug is between the upper and lower limits. After or contemporaneous with deactivating the heater  116  at block  246 , the controller  110  may unlock the lock  112  at block  248  permitting operation at block  250 . 
     It will be recognized that the methods of operation of the system  100  described in  FIGS. 2-6  may be combined with each other. For example, the system may perform both the method according to  FIG. 2  or  FIG. 3  in combination with that of  FIG. 4 . Similarly,  FIG. 4  may be performed with reference to the lapse of a particular time period at block  182  (as illustrated in  FIG. 3  relative to the reservoir) instead of with reference to a particular temperature range. Further, the steps in blocks  156 - 164  in  FIG. 3  may be substituted for those in blocks  200 - 208  in  FIG. 5 . In addition, the steps of activating and deactivating a heater illustrated in blocks  244 ,  246  of  FIG. 6  may be combined with any of the methods of operation illustrated in  FIGS. 2-5 , as would be recognized from the foregoing description (see, e.g.,  FIG. 7  as compared to  FIG. 5 ). 
     Having described the structure and operation of the drug delivery system in general terms (see  FIGS. 1-7 ), further exemplary details are provided regarding the reservoir, drug delivery device, temperature sensor, output device, controller, lock, and heater. In particular, an embodiment of a drug delivery system  300  incorporating the features of  FIG. 1  and adding further details is illustrated in  FIGS. 8-10 . 
       FIG. 8  illustrates a drug delivery system  300 . The system  300  may be a wearable, disposable system. The system  300  may include a disposable housing  302  that may be attached to a patient or wearer with adhesive, for example. 
     The disposable housing  302  may be made of a plastic material. As seen in  FIG. 9 , the housing  302  may be defined by two sections, a plate  304  that is applied against the wearer&#39;s skin, and a dome  306  that is attached to the plate  304 , preferably by a seal at an interface between a peripheral edge  308  of the plate  304  and a peripheral edge  310  of the dome  306 . 
     As shown in  FIG. 9 , the housing  302  has an interior surface  312  defining an interior space  314 , and an exterior surface  316 . In particular, the plate  304  has an interior surface  318  and an exterior surface  320 , and the dome  306  has an interior surface  322  and an exterior surface  324 . According to the illustrated embodiment, the interior surface  312  of the housing  302  is defined by the interior surfaces  318 ,  322  of the plate  304  and the dome  306 , while the exterior surface  316  of the housing  302  is defined by the exterior surfaces  320 ,  324  of the plate  304  and dome  306 . 
     As noted above, the housing  302  may be attached to the skin of the wearer. In some embodiments, an adhesive may be used. The adhesive may be adapted to releasably secure the housing to skin during a single application. As shown in  FIG. 9 , the adhesive is disposed in a layer  326  on a portion  328  of the exterior surface  316  of the housing  302 , and in particular on the exterior surface  320  of the plate  304 . The adhesive is covered with a removable, disposable sheet  330  prior to application of the housing  302  to the skin of the wearer. 
     As seen in  FIGS. 9 and 10 , a reservoir  340 , a drive  342 , a needle  344 , and an injector  346  are disposed in the housing  302 . With reference to the embodiment illustrated in  FIG. 1 , the reservoir  340  may correspond to the reservoir  102 , while the drive  342 , needle  344 , and the injector  346  may correspond to the drug delivery device  104 . It will be recognized that additional components and subassemblies may be provided that would also be considered to correspond to the drug delivery device  104 . 
     In some embodiments, the reservoir  340  may be defined at least in part by a combination of a rigid-walled cylinder or bore  360  having a port  362  at a first end  364  and a plunger  366  fitted to move along a longitudinal axis  368  of the cylinder  360  between a second end  370  and the first end  364  to force drug out of the reservoir  340  through the port  362  ( FIG. 9 ). The movement of the plunger  366  may be caused by the operation of the drive  342 . 
     The drive  342  may be similar in structure and operation to the mechanisms for moving a plunger along a cylinder as may be found in U.S. Pat. Nos. 6,656,158; 6,656,159; 7,128,727; and 7,144,384. As illustrated in  FIG. 11 , the drive  342  may include a plunger arm  372 , a motor  374 , a transmission  376  and a battery  378 . The plunger arm  372  is in contact at least at a first end with the plunger  366  to urge the plunger  366  along the cylinder  360 , and the transmission  376  is coupled to the plunger arm  366  and the motor  374  to cause the plunger arm  372  to move according to the operation of the motor  374 . The battery  378  provides a source of electrical power for the motor  374 . The combination of the motor  374 , transmission  376  and battery  378  may also be referred to as one example of an actuator. 
     According to other embodiments, a non-rigid collapsible pouch may be substituted for the rigid-walled cylinder  360  and the plunger  366  shown in  FIG. 9 . It will be recognized that where the reservoir  360  is in the form of a non-rigid collapsible pouch, a spring-based mechanical system may be used to compress and pressurize the reservoir. According to still further variants, a non-mechanical system may be used to move the plunger  366  or compress the bag. For example, a gas-generating system may be used, including a two-component system wherein the components are kept apart until the gas is to be generated, in which case they are combined. In other embodiments, a swellable gel may be used, wherein the introduction of water from a source internal to the device causes the gel to increase in dimension to move the plunger or compress the pouch. As a further example, a propellant reservoir may be opened and the propellant discharged to move the plunger  366  or compress the bag. Examples of such mechanisms may be found in U.S. Pat. Nos. 5,957,895; 5,858,001; and 5,814,020. 
     According to certain embodiments, the reservoir  340  may be a pre-filled container, such as a pre-filled cartridge or a pre-filled syringe. Alternatively, the delivery system  300  may include a fill port  380  in fluid communication with the reservoir  340 , the fill port  380  adapted to receive a luer tip of a syringe (e.g., syringe illustrated in  FIG. 8 ), although a rubber septum may be used instead, for example. In use, a healthcare provider may inject the drug from the syringe through the fill port  380  into the reservoir  340 , and the syringe may be provided as a pre-filled syringe (filled with any of the materials mentioned herein) to the healthcare provider with the delivery system  300  as a kit. 
     The needle  344  may have a retracted state wherein a pointed end  390  (in fact, the entire needle  344 ) may be withdrawn inside the housing  302  and a deployed state wherein the pointed end  390  projects from the housing  302  (see  FIGS. 12 and 13 ), the injector  346  moving the needle  344  from the retracted state to the deployed state. Examples of exemplary injectors may be found in U.S. Pat. Nos. 7,128,727 and 7,144,384. 
     The needle  344  may be hollow, and may be used to administer the drug directly to the patient. Alternatively, the needle  344  may be used in conjunction with a cannula or catheter  392 , the needle  344  being used to insert the catheter  392  into the patient through the injection site, and the drug passing through the catheter  392  into the patient during administration (see  FIGS. 9 and 10 ). Phrased slightly differently, the system  300  may, according to certain exemplary embodiments, automatically insert a soft cannula into the subcutaneous tissue. 
     As illustrated in  FIGS. 9, 12, and 13 , the housing  302  (specifically the plate  304 ) may have an aperture or opening  394  formed therein to permit the needle  344  (and catheter  392 ) to pass therethrough. According to certain embodiments, the aperture  394  may be unobstructed, such that there is no impediment or obstacle to the movement of the needle  344  (and catheter  392 ) through the opening  394 . However, to better maintain the sterility of the needle  344  and the device&#39;s container closure integrity (CCI), a septum  396  (shown in  FIGS. 12 and 13 ) may be disposed in or over the aperture  394 . 
     The septum  396 , which may be made of a rubber, is disposed between the needle  344  (and the space  314 ) and the patient&#39;s skin with the needle  344  in the retracted state ( FIG. 12 ). In the deployed state ( FIG. 13 ), at least a portion of the needle  344  (i.e., the pointed end  390 ) will depend from the space  314  through the septum  396 . As such, the septum  396  is always present as a barrier between the interior space  314  and the external environment. 
     The system  300  also includes at least one temperature sensor  400 . 
     As illustrated in  FIG. 14 , the at least one temperature sensor  400  may be disposed in different locations throughout the housing  302 . For example, in embodiments where the reservoir  340  includes a cylinder  360  with a port  362  and a plunger  366  moveable within the cylinder  360  relative to the port  362  to force drug out of the port  362 , the temperature sensor  400  may be attached to the plunger  366 . In such a situation, the temperature sensor  400  may be in direct contact with the drug (e.g., disposed on an inner surface of the plunger  366  in direct contact with the drug) or may not be in direct contact with the drug (e.g., disposed or embedded within the plunger  366 ). Alternatively, a sensor  400  may be disposed near or in contact with the reservoir  340 , for example disposed near or in contact with the wall of the reservoir  340 , which may be particularly useful where the reservoir is removable from the remainder of the system  300 . Further, a sensor may be disposed near or on-board a controller. A sensor  400  may also be disposed near or in contact with the battery  378  (see  FIG. 11 ). Where the reservoir  340  includes a cannula or tubing in fluid communication with the reservoir  340 , the temperature sensor  400  may be coupled to the cannula. As illustrated in  FIG. 14 , the temperature sensor  400  is coupled to a cannula in the form of a needle  344 . 
     The temperature sensor  400  may take on a variety of forms. For example, the temperature sensor may be at least one of a resistance temperature detector, a thermocouple, an infrared thermopile, and an assembly comprising a thermally-sensitive label and an optical detector. While these sensors could be solid state devices, the sensors may also be of an RFID-type. An RFID sensor may have an advantage over a solid state device in that an RFID sensor may require neither power nor electrical contact with the device. A solid state device may be connected to a power source (e.g., battery) through a set of contacts. 
     Relative to the examples described above, certain processor chips routinely include a temperature sensor. While some heat may be generated in the processor during operation, this localized increase in temperature may be accounted for relative to the temperature determination using the on-board sensor. The on-board sensor thus may be used to infer the temperature of other components of the delivery device, or even the reservoir, based on their proximity to the sensor. If the heat generation is large enough to overly influence the determined temperature of a distant component, a calculation of heat transfer characteristics within the device and/or reservoir can be used to create a reference map of internal temperatures at various locations. Such a reference map could be stored by the controller for use in the determination of the temperature of components and/or the reservoir. 
     As to the embodiments relating to the temperature sensor attached to the plunger, even if the sensor is placed in indirect contact with the drug product (e.g., the sensor is embedded in the plunger), the sensor and the drug product will equilibrate to the same temperature, particularly during long periods of refrigerated storage. As the product warms, the temperature determined at the plunger should generally track the temperature of the drug in the reservoir. A high thermal conductivity material may be used as an intermediate between the drug in the reservoir and the sensor attached to the plunger to improve the tracking of the two temperatures. Rate information (e.g., rate of temperature change) may be used in addition to the temperature measurements to improve the accuracy and/or correlation to the drug product temperature. 
     As to the embodiments relating to a temperature sensor associated with or disposed proximate to the reservoir (or a temperature-sensitive component), the sensor may be an IR thermopile chip, for example. Such a sensor measures the IR signature of a thermal source, and does so without direct contact with the source. These IR thermopiles may operate in a wavelength range of 0.7 μm to 1000 μm, and may have a footprint of less than 2 mm by 2 mm. An exemplary thermopile chip is the TMP006 chip manufactured by Texas Instruments (Dallas, Tex.), which is optimized for low power consumption and requires a supply current of less than 200 μA. Because such a sensor typically provides a determination of the ambient temperature, the ambient temperature may be used to predict how long the drug (or temperature-sensitive component) will take to reach a temperature above the lower temperature threshold. This prediction may rely on the ambient temperature as well as the thermal mass and thermal transfer properties of the drug (or temperature-sensitive component), and the processor may be programmed to perform the calculation or a reference table may be stored in memory for the processor to access once the ambient temperature is determined. 
     Also in regard to embodiments relating to a temperature sensor associated with or disposed proximate to the reservoir (or a temperature-sensitive component), the sensor may be a thermally-sensitive label used in conjunction with (coupled to) an optical pickup or sensor. The thermally-sensitive label will change its appearance when a threshold temperature is reached. The label may take the form of a physical label, a wax, a lacquer-like paint, or a liquid crystal polymer film, for example. The optical pickup can be used to determine this change in appearance, which can then be correlated with the threshold temperature to make a temperature determination. The optical pickup may have a footprint of less than 2.5 mm by 2.5 mm, and may draw less than 20 μA when in active mode, 0.5 μA when in low-power non-active mode. An exemplary optical pickup or sensor if the MAX44005 sensor sold by Maxim Integrated (San Jose, Calif.). According to such an embodiment, the coupling between the label and the pickup is non-contact, thus preventing direct physical interaction between the label and the pickup. 
     As to the embodiments relating to the temperature sensor attached to the cannula or needle, such a sensor may be formed using thin film sensors (RTDs) or fine gauge wires (thermocouples). Use of such technologies would allow the sensor to be disposed in thermal contact with the needle, and indirect contact with the drug product, by integration into the needle component. As needle components are frequently constructed of materials with high thermal conductivity, a sensor disposed on the needle would improve tracking between the temperature of the needle and the temperature of the drug product passing through the needle. Moreover, with the sensor disposed on the cannula, it may be possible to monitor the body/tissue temperature of the patient at the injection site as well. 
     The system  300  also includes a controller  450  that is coupled to the drive  342  and the injector  346 , the controller  212  operating the drive  342  to deliver a volume of the drug from the reservoir  340  and the injector  346  to move the needle  344  between the retracted and deployed states. As illustrated in  FIG. 10 , the controller is also coupled to the sensor  400 , an output device  452 , a lock  454  and a heater  456 . 
     According to the embodiment illustrated in  FIG. 10 , the controller  450  may include a programmable microprocessor  470 , memory  472 , and a power supply  474 . The power supply  474  may include one or more batteries. According to certain embodiments, the controller  450  may be programmed to determine if the temperature sensor  400  is accurate prior to determining if the temperature of a drug disposed in the reservoir  340  or the drug delivery device (e.g., drive  342 , injector  346 ) is above the upper limit, below the lower limit, or between the upper and lower limits. The determination of accuracy may include a determination that the temperature sensor  400  is connected, or may include a comparison of a determination of the temperature using a signal from the temperature sensor  400  to a determination of the temperature using a signal from another temperature sensor. The controller  450  may also be programmed to adjust a determination of a temperature if the temperature sensor is not accurate, for example with reference to a table stored in memory or through the use of a correction factor. 
     The output device  452  may include at least one of a display, a light and a speaker. According to some embodiments, the output device  452  may include more than one of a display, a light and/or a speaker. The purpose of the output device  452  is to alert the user to a change in operational state of the system, and according to the embodiments described above, this may involve alerting the user to at least two different changes in operational state—one in case of high temperature and another in case of low temperature. Consequently, the output device  452  may include more than one display, light, and/or speaker to provide different alerts for the change in operational state caused by high temperature and the change in operational state caused by low temperature. A single output device  452  may be controlled by the controller  450  to operate differently (e.g., display a different color, or provide a different sound or tone) depending on whether a change in operational state based on a high temperature condition or on a low temperature condition occurs. 
     The heater  456  may be one of a variety of different types. For example, the heater  456  may be at least one of a mechanical heater (e.g., heat from shape memory actuator), an electrical heater, a chemical heater, and a selectable coupling to a heat source. In some embodiments, the electrical heater may include at least one of a resistive heater and a thermoelectric heater (i.e., a heater which provides IR heat generation). In some embodiments, the heat source may include at least one of the controller (e.g., waste heat from the processor circuit board) and a patient to which the drug delivery system is attached (in which case a thermally conductive adhesive may be used). Regardless of the heater used, the fluid path may be lengthened or widened proximate to the heater to improve the localized heating of the fluid between the reservoir and the injection/infusion site. Alternatively, the packaging may provide heating capability, or an adhesive liner may be used to provide the heat (e.g., pulling of adhesive liner activates acrylic adhesive to provide heat). 
     Relative to resistive heaters, such a heater may be constructed by running electrical power through a relatively resistant element, with the electrical energy being converted to heat energy. The heat may then conduct or convect from the source to an adjoining drug product or temperature-sensitive component. The waste heat from the processor circuit board may be generated by resistive heating in the conductor traces, for example. 
     Relative to a thermoelectric heater, such a heater uses the Peltier effect to create a heat flux between the junction to two dissimilar metals with the application of electrical energy. A thermoelectric heater may provide certain advantages, in that the same structure may be used for cooling as well as heating, if so desired. Additionally, there are no moving parts, which should provide greater simplicity and longer life. 
     Relative to chemical heaters, such a heater may include two or more chemicals that react to provide heat. For example, crystallization of a supersaturated solution of sodium acetate may be used, which reaction may be initiated by nucleation at time of use and may provide heat for between 20 minutes and 2 hours depending on the volume of reactants used. 
     The controller  450  also may be a mechanical device, a combination of mechanical devices, a combination of electrical devices (hard-wired circuits or circuit components), or a combination of mechanical and electrical devices.  FIG. 15  illustrates a particular embodiment of a mechanical controller  500  in combination with a reservoir  502 , a needle  504 , and a valve  506  disposed in a fluid flow path  508  between the reservoir  502  and the needle  504 . The device including the controller  500 , reservoir  502 , needle  504 , and valve  506  may include other devices (such as a drive for the reservoir  502  and/or an actuator for the needle  504 ), but these structures have been omitted for ease of explanation. The valve  506  may function as the lock in the embodiments described above, with the valve closed state corresponding to the locked state and the valve open state corresponding to the unlocked state. 
     The controller  500  includes an actuator  510  in the form of a temperature-sensitive material that may be used to change the lock state of the valve/lock  506 , and which actuator  510  is disposed proximate to the drug and/or temperature-sensitive component that is to be monitored. The actuator  510  may include, for example, a strip of shape memory metal, such as nitanol (nickel titanium). Based on the temperature of the strip of shape memory metal, the strip may assume a first shape or a second shape. The temperature at which the strip changes between the first shape and the second shape may correspond to the lower temperature threshold. With the strip in the first shape, the strip may abut the valve  506  to place the valve  506  in its closed state. With the strip in the second shape, the strip may be spaced from the valve  506  so as to permit the valve  506  to assume its open state. Consequently, when the strip is at a temperature below the lower temperature threshold, the strip will ensure that the valve  506  is closed (locked), and when the strip is at a temperature above the lower temperature threshold, the strip will ensure that the valve  506  is open (unlocked). 
     In terms of the embodiments of methods illustrated in  FIGS. 2 and 4 , the controller  500  determines whether the temperature of the drug or a temperature-sensitive component is below a lower temperature threshold based on the shape of the strip of shape memory alloy. If the temperature of the strip is below the temperature at which the strip changes shape, then the strip will actuate the valve  506 , corresponding to activation of the lock. The controller  500  determines if the temperature of the drug or the temperature-sensitive component is above the lower temperature threshold if the strip changes from the first shape to the second shape. If this occurs, the controller  500  unlocks the lock by virtue of the strip being spaced from the valve  506 , permitting the valve to move to its open state, at which point drug may flow from the reservoir  402  to the needle  504 . 
     According to various embodiments, activation of the lock does not require the lock to have been in the unlocked state prior to its activation. The activation of the lock in some embodiments may also include or encompass permitting the lock to remain in its default locked state. As illustrated in  FIG. 16 , a controller may determine (or in the case of an electrical embodiment, may be programmed to determine) if the temperature of a drug disposed in a reservoir exceeds an upper limit at block  530 . If the temperature exceeds the upper limit, the controller may activate an output device at least once at block  532  (e.g., to alert the user that the temperature of the drug is too high for safety) and place the lock in the locked state at block  534 . In some embodiments, placing the lock in the locked state at block  534  includes the controller doing nothing at all because the lock is in the locked state by default. If the temperature is below the upper limit, the controller may determine (or may be programmed to determine) if the temperature of a drug disposed in the reservoir is below a lower limit at block  536 , and if the temperature is below the lower limit, may activate the output device at least once at block  538  (e.g., to alert the user that the temperature of the drug is too low for safety, for comfortable delivery and/or for predictable delivery) and place the lock in the locked state at block  540 . Similar to that described above, in some embodiments, placing the lock in the locked state at block  540  includes the controller doing nothing at all because the lock is in the locked state by default. Further, the controller may determine (or may be programmed to determine) at block  542  if the temperature of the drug is between the upper limit and the lower limit subsequent to block  536  (and blocks  538 ,  540 ). If the temperature is between the upper limit and the lower limit, the controller places the lock in the unlocked state at block  544  thus permitting operation at block  546 . In embodiments where the lock is by default in the locked state, it will also be necessary for the controller to place the lock in the unlocked state at block  548 . 
     The steps of the method according to  FIG. 16  may be expressed in the same manner as those of the method according to  FIG. 2 , for example, except for the fact that the controller must also perform the step of unlocking the lock if it is determined that the temperature of the drug or the temperature-sensitive component is neither above the upper temperature threshold nor below the lower temperature threshold. Step  548  may thus be incorporated into any of the methods illustrated in  FIGS. 2-7  to similar effect in an embodiment where the lock is locked by default. 
     Further embodiments of a method of operation of the device are illustrated in  FIG. 17 . These embodiments differ from the preceding embodiments in that a lock is not activated in all circumstances. Accordingly, as illustrated in  FIG. 17 , a controller according to may determine (or in the case of an electrical embodiment, may be programmed to determine) if the temperature of a drug disposed in a reservoir exceeds an upper limit at block  560 . If the temperature exceeds the upper limit, the controller may activate an output device at least once at block  562  (e.g., to alert the use that the temperature of the drug is too high for safety) and place the lock in the locked state at block  564 . If the temperature is below the upper limit, the controller may determine (or may be programmed to determine) if the temperature of a drug disposed in the reservoir is below a lower limit at block  566 , and if the temperature is below the lower limit, may activate the output device at least once at block  568  (e.g., to alert the user that the temperature of the drug is too low for safety, for comfortable delivery and/or for predictable delivery). According to indicia (e.g., instructions) marked on the external surface of the device (e.g. a cover), for example, the user is informed that upon activation of the output device, the user is to wait a period of time (e.g., five, ten or twenty minutes) before operating the device. However, as indicated at block  570 , the device will not be locked and will be operational even after the output device is activated at block  568 . 
     The presumption underlying such an embodiment as is illustrated in  FIG. 17  is similar to that underlying the embodiment of  FIG. 3 : if a sufficient amount of time is permitted to elapse, the heat from the surroundings will increase the temperature of the drug or sensitive component above the lower temperature threshold. Unlike the embodiment in  FIG. 3 , no lock is activated to prevent use of the system. Optionally, the embodiment of the method according to  FIG. 17  may be further simplified by omitting the step at block  564 , such that the output device is activated to alert the user to the fact that the drug or temperature-sensitive component has exceeded the upper temperature threshold. According to such an embodiment, the activation of the output device at block  562  may differ from the activation of the output device at block  568 , so that the user may differentiate between the two alerts. Moreover, it may be that the device will be permitted to operate after the activation of the output device either at block  562  or at block  568 . 
     Having described the structure and operation of the device, exemplary drugs, medicaments or pharmaceutical products to be contained with the reservoir are discussed below. 
     For example, the drug delivery device or more specifically the reservoir of the device may be filled with colony stimulating factors, such as G-CSF. Such G-CSF agents include, but are not limited to, Neupogen® (filgrastim) and Neulasta® (pegfilgrastim). In various other embodiments, the drug delivery device may be used with various pharmaceutical products, such as an erythropoiesis stimulating agent (ESA), which may be in a liquid or a lyophilized form. An ESA is any molecule that stimulates erythropoiesis, such as Epogen® (epoetin alfa), Aranesp® (darbepoetin alfa), Dynepo® (epoetin delta), Mircera® (methyoxy polyethylene glycol-epoetin beta), Hematide®, MRK-2578, INS-22, Retacrit® (epoetin zeta), Neorecormon® (epoetin beta), Silapo® (epoetin zeta), Binocrit® (epoetin alfa), epoetin alfa Hexal, Abseamed® (epoetin alfa), Ratioepo® (epoetin theta), Eporatio® (epoetin theta), Biopoin® (epoetin theta), epoetin alfa, epoetin beta, epoetin zeta, epoetin theta, and epoetin delta, as well as the molecules or variants or analogs thereof as disclosed in the following patents or patent applications: U.S. Pat. Nos. 4,703,008; 5,441,868; 5,547,933; 5,618,698; 5,621,080; 5,756,349; 5,767,078; 5,773,569; 5,955,422; 5,986,047; 6,583,272; 7,084,245; and 7,271,689; and PCT Publ. Nos. WO 91/05867; WO 95/05465; WO 96/40772; WO 00/24893; WO 01/81405; and WO 2007/136752. 
     An ESA can be an erythropoiesis stimulating protein. As used herein, “erythropoiesis stimulating protein” means any protein that directly or indirectly causes activation of the erythropoietin receptor, for example, by binding to and causing dimerization of the receptor. Erythropoiesis stimulating proteins include erythropoietin and variants, analogs, or derivatives thereof that bind to and activate erythropoietin receptor; antibodies that bind to erythropoietin receptor and activate the receptor; or peptides that bind to and activate erythropoietin receptor. Erythropoiesis stimulating proteins include, but are not limited to, epoetin alfa, epoetin beta, epoetin delta, epoetin omega, epoetin iota, epoetin zeta, and analogs thereof, pegylated erythropoietin, carbamylated erythropoietin, mimetic peptides (including EMP1/hematide), and mimetic antibodies. Exemplary erythropoiesis stimulating proteins include erythropoietin, darbepoetin, erythropoietin agonist variants, and peptides or antibodies that bind and activate erythropoietin receptor (and include compounds reported in U.S. Publ. Nos. 2003/0215444 and 2006/0040858) as well as erythropoietin molecules or variants or analogs thereof as disclosed in the following patents or patent applications: U.S. Pat. Nos. 4,703,008; 5,441,868; 5,547,933; 5,618,698; 5,621,080; 5,756,349; 5,767,078; 5,773,569; 5,955,422; 5,830,851; 5,856,298; 5,986,047; 6,030,086; 6,310,078; 6,391,633; 6,583,272; 6,586,398; 6,900,292; 6,750,369; 7,030,226; 7,084,245; and 7,217,689; US Publ. Nos. 2002/0155998; 2003/0077753; 2003/0082749; 2003/0143202; 2004/0009902; 2004/0071694; 2004/0091961; 2004/0143857; 2004/0157293; 2004/0175379; 2004/0175824; 2004/0229318; 2004/0248815; 2004/0266690; 2005/0019914; 2005/0026834; 2005/0096461; 2005/0107297; 2005/0107591; 2005/0124045; 2005/0124564; 2005/0137329; 2005/0142642; 2005/0143292; 2005/0153879; 2005/0158822; 2005/0158832; 2005/0170457; 2005/0181359; 2005/0181482; 2005/0192211; 2005/0202538; 2005/0227289; 2005/0244409; 2006/0088906; and 2006/0111279; and PCT Publ. Nos. WO 91/05867; WO 95/05465; WO 99/66054; WO 00/24893; WO 01/81405; WO 00/61637; WO 01/36489; WO 02/014356; WO 02/19963; WO 02/20034; WO 02/49673; WO 02/085940; WO 03/029291; WO 2003/055526; WO 2003/084477; WO 2003/094858; WO 2004/002417; WO 2004/002424; WO 2004/009627; WO 2004/024761; WO 2004/033651; WO 2004/035603; WO 2004/043382; WO 2004/101600; WO 2004/101606; WO 2004/101611; WO 2004/106373; WO 2004/018667; WO 2005/001025; WO 2005/001136; WO 2005/021579; WO 2005/025606; WO 2005/032460; WO 2005/051327; WO 2005/063808; WO 2005/063809; WO 2005/070451; WO 2005/081687; WO 2005/084711; WO 2005/103076; WO 2005/100403; WO 2005/092369; WO 2006/50959; WO 2006/02646; and WO 2006/29094. 
     Examples of other pharmaceutical products for use with the device may include, but are not limited to, antibodies such as Vectibix® (panitumumab), Xgeva™ (denosumab) and Prolia™ (denosamab); other biological agents such as Enbrel® (etanercept, TNF-receptor/Fc fusion protein, TNF blocker), Neulasta® (pegfilgrastim, pegylated filgastrim, pegylated G-CSF, pegylated hu-Met-G-CSF), Neupogen® (filgrastim, G-CSF, hu-MetG-CSF), and Nplate® (romiplostim); small molecule drugs such as Sensipar® (cinacalcet). The device may also be used with a therapeutic antibody, a polypeptide, a protein or other chemical, such as an iron, for example, ferumoxytol, iron dextrans, ferric glyconate, and iron sucrose. The pharmaceutical product may be in liquid form, or reconstituted from lyophilized form. 
     Among particular illustrative proteins are the specific proteins set forth below, including fusions, fragments, analogs, variants or derivatives thereof: 
     OPGL specific antibodies, peptibodies, and related proteins, and the like (also referred to as RANKL specific antibodies, peptibodies and the like), including fully humanized and human OPGL specific antibodies, particularly fully humanized monoclonal antibodies, including but not limited to the antibodies described in PCT Publ. No. WO 03/002713, as to OPGL specific antibodies and antibody related proteins, particularly those having the sequences set forth therein, particularly, but not limited to, those denoted therein: 9H7; 18B2; 2D8; 2E11; 16E1; and 22B3, including the OPGL specific antibodies having either the light chain of SEQ ID NO: 2 as set forth therein in  FIG. 2  and/or the heavy chain of SEQ ID NO:4, as set forth therein in  FIG. 4 ; 
     Myostatin binding proteins, peptibodies, and related proteins, and the like, including myostatin specific peptibodies, particularly those described in US Publ. No. 2004/0181033 and PCT Publ. No. WO 2004/058988, including but not limited to peptibodies of the mTN8-19 family, including those of SEQ ID NOS: 305-351, including TN8-19-1 through TN8-19-40, TN8-19 con1 and TN8-19 con2; peptibodies of the mL2 family of SEQ ID NOS: 357-383; the mL15 family of SEQ ID NOS: 384-409; the mL17 family of SEQ ID NOS: 410-438; the mL20 family of SEQ ID NOS: 439-446; the mL21 family of SEQ ID NOS: 447-452; the mL24 family of SEQ ID NOS: 453-454; and those of SEQ ID NOS: 615-631; 
     IL-4 receptor specific antibodies, peptibodies, and related proteins, and the like, particularly those that inhibit activities mediated by binding of IL-4 and/or IL-13 to the receptor, including those described in PCT Publ. No. WO 2005/047331 or PCT Appl. No. PCT/US2004/37242 and in US Publ. No. 2005/112694, particularly in parts pertinent to IL-4 receptor specific antibodies, particularly such antibodies as are described therein, particularly, and without limitation, those designated therein: L1H1; L1H2; L1H3; L1H4; L1H5; L1H6; L1H7; L1H8; L1H9; L1H10; L1H11; L2H1; L2H2; L2H3; L2H4; L2H5; L2H6; L2H7; L2H8; L2H9; L2H10; L2H11; L2H12; L2H13; L2H14; L3H1; L4H1; L5H1; L6H1; 
     Interleukin 1-receptor 1 (“IL1-R1”) specific antibodies, peptibodies, and related proteins, and the like, including but not limited to those described in U.S. Publ. No. 2004/097712A1, parts pertinent to IL1-R1 specific binding proteins, monoclonal antibodies in particular, especially, without limitation, those designated therein: 15CA, 26F5, 27F2, 24E12, and 10H7; 
     Ang2 specific antibodies, peptibodies, and related proteins, and the like, including but not limited to those described in PCT Publ. No. WO 03/057134 and U.S. Publ No. 2003/0229023, particularly in parts pertinent to Ang2 specific antibodies and peptibodies and the like, especially those of sequences described therein and including but not limited to: L1(N); L1(N) WT; L1(N) 1K WT; 2×L1(N); 2×L1(N) WT; Con4 (N), Con4 (N) 1K WT, 2×Con4 (N) 1K; L1C; L1C 1K; 2×L1C; Con4C; Con4C 1K; 2×Con4C 1K; Con4-L1 (N); Con4-L1C; TN-12-9 (N); C17 (N); TN8-8(N); TN8-14 (N); Con 1 (N), also including anti-Ang 2 antibodies and formulations such as those described in PCT Publ. No. WO 2003/030833 particularly Ab526; Ab528; Ab531; Ab533; Ab535; Ab536; Ab537; Ab540; Ab543; Ab544; Ab545; Ab546; A551; Ab553; Ab555; Ab558; Ab559; Ab565; AbF1AbFD; AbFE; AbFJ; AbFK; AbG1D4; AbGC1E8; AbH1C12; AblA1; AblF; AblK, AblP; and AblP, in their various permutations as described therein. 
     NGF specific antibodies, peptibodies, and related proteins, and the like including, in particular, but not limited to those described in US Publ. No. 2005/0074821 and U.S. Pat. No. 6,919,426, as to NGF-specific antibodies and related proteins in this regard, including in particular, but not limited to, the NGF-specific antibodies therein designated 4D4, 4G6, 6H9, 7H2, 14D10 and 14D11; 
     CD22 specific antibodies, peptibodies, and related proteins, and the like, such as those described in U.S. Pat. No. 5,789,554, as to CD22 specific antibodies and related proteins, particularly human CD22 specific antibodies, such as but not limited to humanized and fully human antibodies, including but not limited to humanized and fully human monoclonal antibodies, particularly including but not limited to human CD22 specific IgG antibodies, such as, for instance, a dimer of a human-mouse monoclonal hLL2 gamma-chain disulfide linked to a human-mouse monoclonal hLL2 kappa-chain, including, but limited to, for example, the human CD22 specific fully humanized antibody in Epratuzumab, CAS registry number 501423-23-0; 
     IGF-1 receptor specific antibodies, peptibodies, and related proteins, and the like, such as those described in PCT Publ. No. WO 06/069202, as to IGF-1 receptor specific antibodies and related proteins, including but not limited to the IGF-1 specific antibodies therein designated L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13H13, L14H14, L15H15, L16H16, L17H17, L18H18, L19H19, L20H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26, L27H27, L28H28, L29H29, L30H30, L31H31, L32H32, L33H33, L34H34, L35H35, L36H36, L37H37, L38H38, L39H39, L40H40, L41H41, L42H42, L43H43, L44H44, L45H45, L46H46, L47H47, L48H48, L49H49, L50H50, L51H51, L52H52, and IGF-1R-binding fragments and derivatives thereof; 
     Also among non-limiting examples of anti-IGF-1R antibodies for use in the methods and compositions of the present invention are each and all of those described in: 
     (i) US Publ. No. 2006/0040358 (published Feb. 23, 2006), 2005/0008642 (published Jan. 13, 2005), 2004/0228859 (published Nov. 18, 2004), including but not limited to, for instance, antibody 1A (DSMZ Deposit No. DSM ACC 2586), antibody 8 (DSMZ Deposit No. DSM ACC 2589), antibody 23 (DSMZ Deposit No. DSM ACC 2588) and antibody 18 as described therein; 
     (ii) PCT Publ. No. WO 06/138729 (published Dec. 28, 2006) and WO 05/016970 (published Feb. 24, 2005), and Lu et al., 2004, J Biol. Chem. 279:2856-65, including but not limited to antibodies 2F8, A12, and IMC-A12 as described therein; 
     (iii) PCT Publ. No. WO 07/012614 (published Feb. 1, 2007), WO 07/000328 (published Jan. 4, 2007), WO 06/013472 (published Feb. 9, 2006), WO 05/058967 (published Jun. 30, 2005), and WO 03/059951 (published Jul. 24, 2003); 
     (iv) US Publ. No. 2005/0084906 (published Apr. 21, 2005), including but not limited to antibody 7C10, chimaeric antibody C7C10, antibody h7C10, antibody 7H2M, chimaeric antibody *7C10, antibody GM 607, humanized antibody 7C10 version 1, humanized antibody 7C10 version 2, humanized antibody 7C10 version 3, and antibody 7H2HM, as described therein; 
     (v) US Publ. Nos. 2005/0249728 (published Nov. 10, 2005), 2005/0186203 (published Aug. 25, 2005), 2004/0265307 (published Dec. 30, 2004), and 2003/0235582 (published Dec. 25, 2003) and Maloney et al., 2003, Cancer Res. 63:5073-83, including but not limited to antibody EM164, resurfaced EM164, humanized EM164, huEM164 v1.0, huEM164 v1.1, huEM164 v1.2, and huEM164 v1.3 as described therein; 
     (vi) U.S. Pat. No. 7,037,498 (issued May 2, 2006), US Publ. Nos. 2005/0244408 (published Nov. 30, 2005) and 2004/0086503 (published May 6, 2004), and Cohen, et al., 2005, Clinical Cancer Res. 11:2063-73, e.g., antibody CP-751,871, including but not limited to each of the antibodies produced by the hybridomas having the ATCC accession numbers PTA-2792, PTA-2788, PTA-2790, PTA-2791, PTA-2789, PTA-2793, and antibodies 2.12.1, 2.13.2, 2.14.3, 3.1.1, 4.9.2, and 4.17.3, as described therein; 
     (vii) US Publ. Nos. 2005/0136063 (published Jun. 23, 2005) and 2004/0018191 (published Jan. 29, 2004), including but not limited to antibody 19D12 and an antibody comprising a heavy chain encoded by a polynucleotide in plasmid 15H12/19D12 HCA (γ4), deposited at the ATCC under number PTA-5214, and a light chain encoded by a polynucleotide in plasmid 15H12/19D12 LCF (κ), deposited at the ATCC under number PTA-5220, as described therein; and 
     (viii) US Publ. No. 2004/0202655 (published Oct. 14, 2004), including but not limited to antibodies PINT-6A1, PINT-7A2, PINT-7A4, PINT-7A5, PINT-7A6, PINT-8A1, PINT-9A2, PINT-11A1, PINT-11A2, PINT-11A3, PINT-11A4, PINT-11A5, PINT-11A7, PINT-11A12, PINT-12A1, PINT-12A2, PINT-12A3, PINT-12A4, and PINT-12A5, as described therein, particularly as to the aforementioned antibodies, peptibodies, and related proteins and the like that target IGF-1 receptors; 
     B-7 related protein 1 specific antibodies, peptibodies, related proteins and the like (“B7RP-1,” also is referred to in the literature as B7H2, ICOSL, B7h, and CD275), particularly B7RP-specific fully human monoclonal IgG2 antibodies, particularly fully human IgG2 monoclonal antibody that binds an epitope in the first immunoglobulin-like domain of B7RP-1, especially those that inhibit the interaction of B7RP-1 with its natural receptor, ICOS, on activated T cells in particular, especially, in all of the foregoing regards, those disclosed in U.S. Publ. No. 2008/0166352 and PCT Publ. No. WO 07/011941, as to such antibodies and related proteins, including but not limited to antibodies designated therein as follow: 16H (having light chain variable and heavy chain variable sequences SEQ ID NO:1 and SEQ ID NO:7 respectively therein); 5D (having light chain variable and heavy chain variable sequences SEQ ID NO:2 and SEQ ID NO:9 respectively therein); 2H (having light chain variable and heavy chain variable sequences SEQ ID NO:3 and SEQ ID NO:10 respectively therein); 43H (having light chain variable and heavy chain variable sequences SEQ ID NO:6 and SEQ ID NO:14 respectively therein); 41H (having light chain variable and heavy chain variable sequences SEQ ID NO:5 and SEQ ID NO:13 respectively therein); and 15H (having light chain variable and heavy chain variable sequences SEQ ID NO:4 and SEQ ID NO:12 respectively therein). 
     IL-15 specific antibodies, peptibodies, and related proteins, and the like, such as, in particular, humanized monoclonal antibodies, particularly antibodies such as those disclosed in U.S. Publ. Nos. 2003/0138421; 2003/023586; and 2004/0071702; and U.S. Pat. No. 7,153,507, as to IL-15 specific antibodies and related proteins, including peptibodies, including particularly, for instance, but not limited to, HuMax IL-15 antibodies and related proteins, such as, for instance, 146B7; 
     IFN gamma specific antibodies, peptibodies, and related proteins and the like, especially human IFN gamma specific antibodies, particularly fully human anti-IFN gamma antibodies, such as, for instance, those described in US Publ. No. 2005/0004353, as to IFN gamma specific antibodies, particularly, for example, the antibodies therein designated 1118; 1118*; 1119; 1121; and 1121*. The entire sequences of the heavy and light chains of each of these antibodies, as well as the sequences of their heavy and light chain variable regions and complementarity determining regions and in Thakur et al., Mol. Immunol. 36:1107-1115 (1999). Specific antibodies include those having the heavy chain of SEQ ID NO: 17 and the light chain of SEQ ID NO:18; those having the heavy chain variable region of SEQ ID NO:6 and the light chain variable region of SEQ ID NO:8; those having the heavy chain of SEQ ID NO:19 and the light chain of SEQ ID NO:20; those having the heavy chain variable region of SEQ ID NO:10 and the light chain variable region of SEQ ID NO:12; those having the heavy chain of SEQ ID NO:32 and the light chain of SEQ ID NO:20; those having the heavy chain variable region of SEQ ID NO:30 and the light chain variable region of SEQ ID NO:12; those having the heavy chain sequence of SEQ ID NO:21 and the light chain sequence of SEQ ID NO:22; those having the heavy chain variable region of SEQ ID NO:14 and the light chain variable region of SEQ ID NO:16; those having the heavy chain of SEQ ID NO:21 and the light chain of SEQ ID NO:33; and those having the heavy chain variable region of SEQ ID NO:14 and the light chain variable region of SEQ ID NO:31, as disclosed in the foregoing US Publication. A specific antibody contemplated is antibody 1119 as disclosed in foregoing US Publication and having a complete heavy chain of SEQ ID NO:17 as disclosed therein and having a complete light chain of SEQ ID NO:18 as disclosed therein; 
     TALL-1 specific antibodies, peptibodies, and the related proteins, and the like, and other TALL specific binding proteins, such as those described in U.S. Publ. Nos. 2003/0195156 and 2006/0135431, as to TALL-1 binding proteins, particularly the molecules of Tables 4 and 5B. 
     Parathyroid hormone (“PTH”) specific antibodies, peptibodies, and related proteins, and the like, such as those described in U.S. Pat. No. 6,756,480, particularly in parts pertinent to proteins that bind PTH; 
     Thrombopoietin receptor (“TPO-R”) specific antibodies, peptibodies, and related proteins, and the like, such as those described in U.S. Pat. No. 6,835,809, particularly in parts pertinent to proteins that bind TPO-R; 
     Hepatocyte growth factor (“HGF”) specific antibodies, peptibodies, and related proteins, and the like, including those that target the HGF/SF:cMet axis (HGF/SF:c-Met), such as the fully human monoclonal antibodies that neutralize hepatocyte growth factor/scatter (HGF/SF) described in US Publ. No. 2005/0118643 and PCT Publ. No. WO 2005/017107, huL2G7 described in U.S. Pat. No. 7,220,410 and OA-5d5 described in U.S. Pat. Nos. 5,686,292 and 6,468,529 and in PCT Publ. No. WO 96/38557, particularly in parts pertinent to proteins that bind HGF; 
     TRAIL-R2 specific antibodies, peptibodies, related proteins and the like, such as those described in U.S. Pat. No. 7,521,048, particularly in parts pertinent to proteins that bind TRAIL-R2; 
     Activin A specific antibodies, peptibodies, related proteins, and the like, including but not limited to those described in US Publ. No. 2009/0234106, particularly in parts pertinent to proteins that bind Activin A; 
     TGF-beta specific antibodies, peptibodies, related proteins, and the like, including but not limited to those described in U.S. Pat. No. 6,803,453 and US Publ. No. 2007/0110747, particularly in parts pertinent to proteins that bind TGF-beta; 
     Amyloid-beta protein specific antibodies, peptibodies, related proteins, and the like, including but not limited to those described in PCT Publ. No. WO 2006/081171, particularly in parts pertinent to proteins that bind amyloid-beta proteins. One antibody contemplated is an antibody having a heavy chain variable region comprising SEQ ID NO: 8 and a light chain variable region having SEQ ID NO: 6 as disclosed in the International Publication; 
     c-Kit specific antibodies, peptibodies, related proteins, and the like, including but not limited to those described in Publ. No. 2007/0253951 particularly in parts pertinent to proteins that bind c-Kit and/or other stem cell factor receptors; 
     OX40L specific antibodies, peptibodies, related proteins, and the like, including but not limited to those described in U.S. application Ser. No. 11/086,289 particularly in parts pertinent to proteins that bind OX40L and/or other ligands of the OX40 receptor; and 
     Other exemplary proteins, including Activase® (alteplase, tPA); Aranesp® (darbepoetin alfa); Epogen® (epoetin alfa, or erythropoietin); GLP-1, Avonex® (interferon beta-1a); Bexxar® (tositumomab, anti-CD22 monoclonal antibody); Betaseron® (interferon-beta); Campath® (alemtuzumab, anti-CD52 monoclonal antibody); Dynepo® (epoetin delta); Velcade® (bortezomib); MLN0002 (anti-α4ß7 mAb); MLN1202 (anti-CCR2 chemokine receptor mAb); Enbrel® (etanercept, TNF-receptor/Fc fusion protein, TNF blocker); Eprex® (epoetin alfa); Erbitux® (cetuximab, anti-EGFR/HER1/c-ErbB-1); Genotropin® (somatropin, Human Growth Hormone); Herceptin® (trastuzumab, anti-HER2/neu (erbB2) receptor mAb); Humatrope® (somatropin, Human Growth Hormone); Humira® (adalimumab); insulin in solution; Infergen® (interferon alfacon-1); Natrecor® (nesiritide; recombinant human B-type natriuretic peptide (hBNP); Kineret® (anakinra); Leukine® (sargamostim, rhuGM-CSF); LymphoCide® (epratuzumab, anti-CD22 mAb); Benlysta™ (lymphostat B, belimumab, anti-BlyS mAb); Metalyse® (tenecteplase, t-PA analog); Mircera® (methoxy polyethylene glycol-epoetin beta); Mylotarg® (gemtuzumab ozogamicin); Raptiva® (efalizumab); Cimzia® (certolizumab pegol, CDP 870); Soliris™ (eculizumab); pexelizumab (anti-C5 complement); Numax® (MEDI-524); Lucentis® (ranibizumab); Panorex® (17-1A, edrecolomab); Trabio® (lerdelimumab); TheraCim hR3 (nimotuzumab); Omnitarg (pertuzumab, 2C4); Osidem® (IDM-1); OvaRex® (B43.13); Nuvion® (visilizumab); cantuzumab mertansine (huC242-DM1); NeoRecormon® (epoetin beta); Neumega® (oprelvekin, human interleukin-11); Neulasta® (pegylated filgastrim, pegylated G-CSF, pegylated hu-Met-G-CSF); Neupogen® (filgrastim, G-CSF, hu-MetG-CSF); Orthoclone OKT3® (muromonab-CD3, anti-CD3 monoclonal antibody); Procrit® (epoetin alfa); Remicade® (infliximab, anti-TNFα monoclonal antibody); Reopro® (abciximab, anti-GP IIb/IIia receptor monoclonal antibody); Actemra® (anti-IL6 Receptor mAb); Avastin® (bevacizumab), HuMax-CD4 (zanolimumab); Rituxan® (rituximab, anti-CD20 mAb); Tarceva® (erlotinib); Roferon-A®-(interferon alfa-2a); Simulect® (basiliximab); Prexige® (lumiracoxib); Synagis® (palivizumab); 146B7-CHO (anti-IL15 antibody, see U.S. Pat. No. 7,153,507); Tysabri® (natalizumab, anti-α4 integrin mAb); Valortim® (MDX-1303, anti- B. anthracis  protective antigen mAb); ABthrax™; Vectibix® (panitumumab); Xolair® (omalizumab); ETI211 (anti-MRSA mAb); IL-1 trap (the Fc portion of human IgG1 and the extracellular domains of both IL-1 receptor components (the Type I receptor and receptor accessory protein)); VEGF trap (Ig domains of VEGFR1 fused to IgG1 Fc); Zenapax® (daclizumab); Zenapax® (daclizumab, anti-IL-2Ra mAb); Zevalin® (ibritumomab tiuxetan); Zetia® (ezetimibe); Orencia® (atacicept, TACI-Ig); anti-CD80 monoclonal antibody (galiximab); anti-CD23 mAb (lumiliximab); BR2-Fc (huBR3/huFc fusion protein, soluble BAFF antagonist); CNTO 148 (golimumab, anti-TNFα mAb); HGS-ETR1 (mapatumumab; human anti-TRAIL Receptor-1 mAb); HuMax-CD20 (ocrelizumab, anti-CD20 human mAb); HuMax-EGFR (zalutumumab); M200 (volociximab, anti-α5β1 integrin mAb); MDX-010 (ipilimumab, anti-CTLA-4 mAb and VEGFR-1 (IMC-18F1); anti-BR3 mAb; anti- C. difficile  Toxin A and Toxin B C mAbs MDX-066 (CDA-1) and MDX-1388); anti-CD22 dsFv-PE38 conjugates (CAT-3888 and CAT-8015); anti-CD25 mAb (HuMax-TAC); anti-CD3 mAb (NI-0401); adecatumumab; anti-CD30 mAb (MDX-060); MDX-1333 (anti-IFNAR); anti-CD38 mAb (HuMax CD38); anti-CD40L mAb; anti-Cripto mAb; anti-CTGF Idiopathic Pulmonary Fibrosis Phase I Fibrogen (FG-3019); anti-CTLA4 mAb; anti-eotaxinl mAb (CAT-213); anti-FGF8 mAb; anti-ganglioside GD2 mAb; anti-ganglioside GM2 mAb; anti-GDF-8 human mAb (MYO-029); anti-GM-CSF Receptor mAb (CAM-3001); anti-HepC mAb (HuMax HepC); anti-IFNα mAb (MEDI-545, MDX-1103); anti-IGF1R mAb; anti-IGF-1R mAb (HuMax-Inflam); anti-IL12 mAb (ABT-874); anti-IL12/IL23 mAb (CNTO 1275); anti-IL13 mAb (CAT-354); anti-IL2Ra mAb (HuMax-TAC); anti-IL5 Receptor mAb; anti-integrin receptors mAb (MDX-018, CNTO 95); anti-IP10 Ulcerative Colitis mAb (MDX-1100); anti-LLY antibody; BMS-66513; anti-Mannose Receptor/hCGβ mAb (MDX-1307); anti-mesothelin dsFv-PE38 conjugate (CAT-5001); anti-PD1 mAb (MDX-1106 (ONO-4538)); anti-PDGFRα antibody (IMC-3G3); anti-TGFß mAb (GC-1008); anti-TRAIL Receptor-2 human mAb (HGS-ETR2); anti-TWEAK mAb; anti-VEGFR/Flt-1 mAb; anti-ZP3 mAb (HuMax-ZP3); NVS Antibody #1; and NVS Antibody #2. 
     Also included can be a sclerostin antibody, such as but not limited to romosozumab, blosozumab, or BPS 804 (Novartis). Further included can be therapeutics such as rilotumumab, bixalomer, trebananib, ganitumab, conatumumab, motesanib diphosphate, brodalumab, vidupiprant, panitumumab, denosumab, NPLATE, PROLIA, VECTIBIX or XGEVA. Additionally, included in the device can be a monoclonal antibody (IgG) that binds human Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), e.g. U.S. Pat. No. 8,030,547, U.S. Ser. No. 13/469,032, WO2008/057457, WO2008/057458, WO2008/057459, WO2008/063382, WO2008/133647, WO2009/100297, WO2009/100318, WO2011/037791, WO2011/053759, WO2011/053783, WO2008/125623, WO2011/072263, WO2009/055783, WO2012/0544438, WO2010/029513, WO2011/111007, WO2010/077854, WO2012/088313, WO2012/101251, WO2012/101252, WO2012/101253, WO2012/109530, and WO2001/031007. 
     Also included can be talimogene laherparepvec or another oncolytic HSV for the treatment of melanoma or other cancers. Examples of oncolytic HSV include, but are not limited to talimogene laherparepvec (U.S. Pat. Nos. 7,223,593 and 7,537,924); OncoVEXGALV/CD (U.S. Pat. No. 7,981,669); OrienX010 (Lei et al., 2013, World Journal of Gastroenterology, 19:5138-5143); G207, 1716; NV1020; NV12023; NV1034 and NV1042 (Vargehes et al. 2002, Cancer Gene Ther, 2002, 9 (12): 967-978). 
     Also included are TIMPs. TIMPs are endogenous tissue inhibitors of metalloproteinases (TIMPs) and are important in many natural process. TIMP-3 is expressed by various cells or and is present in the extracellular matrix; it inhibits all the major cartilage-degrading metalloproteases, and may play a role in role in many degradative diseases of connective tissue, including rheumatoid arthritis and osteoarthritis, as well as in cancer and cardiovascular conditions. The amino acid sequence of TIMP-3, and the nucleic acid sequence of a DNA that encodes TIMP-3, are disclosed in U.S. Pat. No. 6,562,596. Description of TIMP mutations can be found in U.S. 61/782,613, U.S. 61/798,160, U.S. 61/802,988, and US 61/940,67. 
     Also included are antagonistic antibodies for human calcitonin gene-related peptide (CGRP) receptor and bispecific antibody molecule that target the CGRP receptor and other headache targets. Further information concerning these molecule can be found in WO2A075238A1. 
     Additionally, a bispecific T cell engager antibody (BiTe), e.g. Blinotumomab can be used in the device. Alternatively, included can be an APJ large molecule agonist e.g., apelin or analogues thereof in the device. Information relating to such molecules can be found in PCT/2013/075773. 
     Although the preceding text sets forth a detailed description of different embodiments of the invention, it should be understood that the legal scope of the invention is defined by the words of the claims set forth at the end of this patent. The detailed description is to be construed as exemplary only and does not describe every possible embodiment of the invention because describing every possible embodiment would be impractical, if not impossible. Numerous alternative embodiments could be implemented, using either current technology or technology developed after the filing date of this patent, which would still fall within the scope of the claims defining the invention. 
     It should also be understood that, unless a term is expressly defined in this patent using the sentence “As used herein, the term ‘ —————— ’ is hereby defined to mean . . . ” or a similar sentence, there is no intent to limit the meaning of that term, either expressly or by implication, beyond its plain or ordinary meaning, and such term should not be interpreted to be limited in scope based on any statement made in any section of this patent (other than the language of the claims). To the extent that any term recited in the claims at the end of this patent is referred to in this patent in a manner consistent with a single meaning, that is done for sake of clarity only so as to not confuse the reader, and it is not intended that such claim term be limited, by implication or otherwise, to that single meaning. Finally, unless a claim element is defined by reciting the word “means” and a function without the recital of any structure, it is not intended that the scope of any claim element be interpreted based on the application of 35 U.S.C. § 112, sixth paragraph.